The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: LBH589 in Refractory Myelodysplastic Syndromes (MDS)
Official Title: A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients
Study ID: NCT00594230
Brief Summary: This will be a single arm Phase II study.
Detailed Description: LBH589 (20 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued if there is evidence of disease progression, unacceptable toxicity and/or at the discretion of the investigator.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Florida Cancer Specialists, Fort Myers, Florida, United States
Northeast Georgia Medical Center, Gainesville, Georgia, United States
Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Oncology Hematology Care, Cincinnati, Ohio, United States
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Name: Ian W. Flinn, M.D.
Affiliation: SCRI Development Innovations, LLC
Role: STUDY_CHAIR